MENU
+Compare
IMMP
Stock ticker: NASDAQ
AS OF
Sep 16 closing price
Price
$1.69
Change
-$0.04 (-2.31%)
Capitalization
243.98M

IMMP stock forecast, quote, news & analysis

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease... Show more

Industry: #Biotechnology
IMMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for IMMP with price predictions
Sep 16, 2025

IMMP sees its Stochastic Oscillator ascends from oversold territory

On September 12, 2025, the Stochastic Oscillator for IMMP moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 58 instances where the indicator left the oversold zone. In of the 58 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 15, 2025. You may want to consider a long position or call options on IMMP as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IMMP just turned positive on September 15, 2025. Looking at past instances where IMMP's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMMP advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

IMMP moved below its 50-day moving average on September 16, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IMMP crossed bearishly below the 50-day moving average on September 02, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMMP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IMMP broke above its upper Bollinger Band on September 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IMMP entered a downward trend on September 15, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IMMP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.597) is normal, around the industry mean (20.607). P/E Ratio (0.000) is within average values for comparable stocks, (53.283). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.160). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (333.412).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.89B. The market cap for tickers in the group ranges from 58 to 100.82B. VRTX holds the highest valuation in this group at 100.82B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 36%. NDTP experienced the highest price growth at 1,681%, while ATYR experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 86%. For the same stocks of the Industry, the average monthly volume growth was 21% and the average quarterly volume growth was 46%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 82
Price Growth Rating: 57
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: -22 (-100 ... +100)
View a ticker or compare two or three
IMMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of anti-cancer therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
264 George Street
Phone
+61 283157003
Employees
24
Web
https://www.immutep.com